Sucampo Pharmaceuticals Announces Webcast of Its Presentation at the 2017 Leerink Partners Roundtable Series: Rare Disease & ...
September 21 2017 - 8:25AM
Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global
biopharmaceutical company, today announced that it will participate
in a fireside chat at the 2017 Leerink Partners Roundtable Series:
Rare Disease & Immuno-Oncology on Wednesday, September 27th at
3:30PM Eastern.
Investors interested in arranging a meeting with the Company's
management during this conference should contact the conference
coordinator.
The fireside chat will be webcast live and may be accessed from
the Event Calendar page of Sucampo's website at
http://www.sucampo.com/investors/events-presentations/. A replay of
the webcast will also be available on the Company's website for
several days after the live event. To ensure a timely connection,
it is recommended that users register at least 15 minutes prior to
the scheduled webcast.
About Sucampo Pharmaceuticals,
Inc.
Sucampo Pharmaceuticals, Inc. is a biopharmaceutical company
focused on the development and commercialization of highly
specialized medicines. Sucampo has a late-stage pipeline of product
candidates in clinical development for orphan disease areas,
including VTS-270, a mixture of 2-hydroxypropyl-B-cyclodextrins
with a specific compositional fingerprint that has been granted
orphan designation in the U.S. and Europe and is in a pivotal Phase
2/3 clinical trial for the treatment of Niemann-Pick Disease Type
C-1, a rare progressive genetic disorder. VTS-270 has also been
granted breakthrough therapy designation in the U.S. Sucampo has an
exclusive option for the North American rights to CPP-1X/sulindac,
which is in Phase 3 development for the treatment of familial
adenomatous polyposis and has been granted orphan drug designation
in the U.S. The company has two marketed products – AMITIZA and
RESCULA. For more information, please visit www.sucampo.com.
The Sucampo logo and the tagline, The Science of
Innovation, are registered trademarks of Sucampo AG. AMITIZA is a
registered trademark of Sucampo AG.
Follow us on Twitter (@Sucampo_Pharma). Follow
us on LinkedIn (Sucampo Pharmaceuticals).Twitter
LinkedIn
Contact:Sucampo Pharmaceuticals, Inc.Silvia
TaylorSenior Vice President, Investor Relations and Corporate
Affairs1-240-223-3718staylor@sucampo.com
Sucampo Pharmaceuticals, Inc. (delisted) (NASDAQ:SCMP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Sucampo Pharmaceuticals, Inc. (delisted) (NASDAQ:SCMP)
Historical Stock Chart
From Apr 2023 to Apr 2024